Syndax Pharmaceuticals (SNDX) Restructuring Costs (2024 - 2026)

Syndax Pharmaceuticals' Restructuring Costs history runs 3 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• In Q1 2026, Restructuring Costs rose 16.5% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $24.0 million (down 4.91% YoY), while the FY2025 annual figure was $23.3 million, up 34.33% from the prior year.
• Restructuring Costs was $5.1 million for Q1 2026 at Syndax Pharmaceuticals, up from $4.8 million in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $11.8 million in Q2 2024 to a low of $3.9 million in Q3 2024.
• Historically, Restructuring Costs has averaged $5.9 million across 3 years, with a median of $5.0 million in 2025.
• Biggest YoY gain for Restructuring Costs was 136.27% in 2025; the steepest drop was 57.58% in 2025.
• A 3-year view of Restructuring Costs shows it stood at $5.2 million in 2024, then slipped by 8.45% to $4.8 million in 2025, then grew by 7.11% to $5.1 million in 2026.
• The last three Restructuring Costs figures came in at $5.1 million (Q1 2026), $4.8 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.